Latest Breaking News On - Corporate contact - Page 1 : comparemela.com

OCEANPAL : REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2024 Form 6 K

FORM 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 .

Edward nebbMargarita veniouCorporate development governanceExchange commissionOceanpal incBaltic exchangeCorporate contactCorporate developmentGovernance officerMedia relationsEmployment profileBulk carriersBaltic panamax indexSelected financialPrivate securities litigation reform actMiddle east

Oceanpal Inc Announces Results Of 2024 Annual Meeting Of Shareholders

Oceanpal Inc Announces Results Of 2024 Annual Meeting Of Shareholders
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Ernst young hellasEdward nebbcommExchange commissionCompany proxy statementMargarita veniouchief corporate development governanceCompany annual meeting of shareholders theOceanpal incAnnual meetingProxy statementPrivate securities litigation reform actMiddle eastCorporate contactMargarita veniouchief corporate developmentGovernance officerMedia relationsEdward nebbcomm counsellors

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesJack kelleher dan mooreKevin moranVanda pharmaceuticals incCompany nasdaqPrnewswire vanda pharmaceuticals incFuture pakContingent value rightsVanda pharmaceuticalsCorporate contactVice presidentChief financial officerTreasurer vanda pharmaceuticalsJack kelleher

Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640

LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation Rhythm to advance LB54640 in two Phase 2 clinical trials BOSTON, Jan. 04, 2024 Rhythm Pharmaceuticals,.

South koreaUnited statesUnited kingdomDavid connollyDavid meekerJunil kim junamAdam daleyCorporate communicationsUnited kingdom medicines healthcare products regulatory agencyRhythm pharmaceuticals incEuropean commissionEuropean unionLg chem life sciences companyExchange commissionLg chem ltdRhythm pharmaceuticals

Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG

SAN CARLOS, Calif. (BUSINESS WIRE) Dec 11, 2023

United statesSan carlosComunidad autonoma de catalunaPeter mcwilliamsJessica yinglingSteven axonMercedes serranoLittle dog communications incGlycomine incSant joanOrphan drug designationRare pediatric disease designationCorporate contactBusiness wire